Salute e Benessere

NANOBIOTIX Provides Business Update and Financial Results for the First Half of…

Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3Upfront payment and first equity tranche received by Nanobiotix post H1 2023 from agreement with Janssen extends cash runway into the first quarter of 2024 and second quarter if the cash covenant of the European Investment Bank (EIB) was not applicableBolstering of clinical oncology development and commercialization...
Nasdaq GlobeNewswire
26/09/2023

GENFIT Announces Publication in Nature Medicine Confirming the Performance of…

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland);September26 , 2023-GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the publication of data demonstrating the effectiveness of its non-alcoholic steatohepatitis (NASH) 1diagnostic technology NIS4 ®by the FNIH's 2NIMBLE3project in the scientific...
Nasdaq GlobeNewswire
26/09/2023

IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2023

Aggregatedpresentationbydayandbymarket NameofissuerIdentificationcodeof issuer(Legal Entity Identifier)Day of transactionIdentificationcodeof financialinstrumentAggregated daily volume(innumber of shares)Dailyweightedaveragepriceof the purchased shares *Market(MICCode) IPSEN549300M6SGDPB4Z94P1118/09/2023FR001025915050125.80AQEUIPSEN549300M6SGDPB4Z94P1118/09/2023...
Nasdaq GlobeNewswire
26/09/2023

Crossject reports financial results and business highlights for first half of…

Press Release Crossjectreports financial results and business highlights for first half of 2023 Strong progress in bringing drugs for use in emergency situations towards the marketFurther strengthening of financial structure to accelerate company's developmentConcluded licensing agreement for ZENEO® Midazolam for Australia and New ZealandProgress in the operating income, net result, and cash flows Dijon, France September 26 , 2023 , 17:35 CET -- Crossject ...
Nasdaq GlobeNewswire
26/09/2023

Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

PanCAN recently followed up their selection of pelareorep—the leading drug candidate of Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC)—for their pivotal Phase 3 trial, by rewarding the drug's developer with its second annual PanCAN Therapeutic Accelerator Award. The award comes with a US$5 million grant to further develop leading-edge treatments. PanCAN recently followed up their selection of pelareorep—the leading drug candidate ofOncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC)—for...
PR Newswire
26/09/2023

Transactions in connection with share buy-back program

Company announcement no. 49 - 2326 September 2023 Transactions in connection with share buy-back program On 3 August 2023 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 38 - 23. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules...
Nasdaq GlobeNewswire
26/09/2023

Oxitec partners with CSIRO, Australia's national science agency, to launch…

In addition to posing a major disease risk to billions of people, the Aedes albopictus mosquito is an aggressive daytime biter, causing major nuisance and hindering outdoor activities in many parts of the world. Infamous for being spread globally via international shipping, car tyres and ornamental 'lucky bamboo', Aedes albopictus continues to invade new territories. Experts predict that if it continues to spread uncontrolled it will pose a disease threat to more than 6 billion people. Aedes…
PR Newswire
26/09/2023

Digital Pathology Market size worth USD 1719.31 Million, Globally, by 2030 at…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=1948 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=1948 Browse in-depth TOCon" Digital Pathology Market " 202 - Pages 126 – Tables 37 – Figures Global Digital Pathology Market: Transforming Healthcare Through Technological Advancements Amidst Challenges The Global Digital Pathology Market, a pivotal segment within the field of pathology,...
PR Newswire
26/09/2023

Respiratory Care Devices Market worth $31.8 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=368 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=368 Browse in-depth TOC on "Respiratory Care Devices Market" 556 - Tables 61 - Figures 468 - Pages Respiratory Care Devices Market Scope: The pulse oximeters segment holds the major share of the respiratory care monitoring devices market. Based on product, the respiratory care...
PR Newswire
26/09/2023

Nitrile Disposable Gloves Market Size to Grow USD 13940 Million By 2029, at a…

Major Factors Driving The Growth Of The Nitrile Gloves Market Are Major Factors Driving The Growth Of The Nitrile Gloves Market Are Increased demand from end-use industries, rising healthcare costs, increased importance of workplace safety, and expanding awareness of healthcare-associated infections are anticipated to propel market expansion. Browse The Table of Contents And List of Figures At https://reports.valuates.com/market-reports/QYRE-Auto-3L9287/global-nitrile-gloves ...
PR Newswire
26/09/2023

Sexual Wellness Market to Reach $31.6 Billion, Globally, by 2032 at 4.9% CAGR…

Grab Sample PDF Before It's Gone: https://www.alliedmarketresearch.com/request-sample/6758 Grab Sample PDF Before It's Gone:https://www.alliedmarketresearch.com/request-sample/6758 Sexual wellness products are specialized items created and marketed with the explicit aim of augmenting and endorsing sexual health, enjoyment, and safety. These products are crafted to enhance comfort, heighten arousal, advocate for safer sexual behaviors, and address a range of concerns associated with...
PR Newswire
26/09/2023

Global Medical Device Packaging Market Size Expected to Reach $50 Billion By…

Sharps Technology Inc. (NASDAQ: STSS and STSSW) BREAKING NEWS: Sharps Technology Signs Asset Purchase Agreement to Acquire InjectEZ Specialty Copolymer Syringe Manufacturing Facility and a 10-Year Purchase Agreement for Over $400 Millionfrom Nephron Pharmaceuticals - Sharps Technology Inc. (NASDAQ: STSS and STSSW) BREAKING NEWS : Sharps Technology Signs Asset Purchase Agreement to Acquire InjectEZ Specialty Copolymer Syringe Manufacturing Facility and a 10-Year Purchase Agreement for...
PR Newswire
26/09/2023

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin…

The primary objective of the Phase I study is to evaluate safety and pharmacokinetics of Hutrukin in healthy volunteers. Sequential dose escalation was conducted using three cohorts of subjects, each receiving a single intravenous infusion of either placebo or Hutrukin, with eight subjects in each cohort.Hutrukin is a candidate drug being developed to reduce brain injury following ischemic stroke. Globally, one in four people over age 25 will experience a stroke—the leading cause of...
Nasdaq GlobeNewswire
26/09/2023

Biogen Completes Acquisition of Reata Pharmaceuticals

Reata acquisition bolsters Biogen's rare disease portfolio with the addition of SKYCLARYS ®(omaveloxolone), the first and only FDA approved treatment for Friedreich's ataxia in the U.S.CAMBRIDGE, Mass., Sept.26, 2023(GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result...
Nasdaq GlobeNewswire
26/09/2023

Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic…

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) BREAKING NEWS: THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS - In an effort to continue accelerating new treatment options for people with pancreatic cancer, the Pancreatic Cancer Action Network (PanCAN) today announced Oncolytics Biotech, Inc. as the recipient of its second annual PanCAN Therapeutic Accelerator Award. Oncolytics…
PR Newswire
26/09/2023

Sirius Medical collaborates with GE Healthcare to showcase the Pintuition® and…

Sirius Medical has previously participated in The One-Stop Clinic™, a pioneering concept introduced by GE HealthCare. The One-Stop Clinic approach marks a paradigm shift towards the delivery of value-based care, redefining the full care pathway experience for patients facing breast cancer. Sirius Medical has previously participated in The One-Stop Clinic™, a pioneering concept introduced by GE HealthCare. The One-Stop Clinic approach marks a paradigm shift towards the delivery of value-based...
PR Newswire
26/09/2023

LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH…

As a result of the Arrangement, the Shares will no longer be listed on the Nasdaq Capital Market. In addition, the Company will submit an application to cease to be a reporting issuer under applicable Canadian securities law, will file a certification and notice on Form 15 with the U.S. Securities and Exchange Commission to suspend its reporting obligations under U.S. securities laws and will otherwise terminate the Company's public reporting requirements. As a result of the Arrangement, the...
PR Newswire
26/09/2023

THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE…

The combination of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab was granted Fast Track designation by the FDA last year and has already been selected for inclusion in the Precision Promise SMclinical trial platform, which is anticipated to open in early 2024. Testing pelareorep in combination with FOLFIRINOX expands the approach so all patients with advanced pancreatic cancer could have the opportunity to benefit from this innovative immunotherapeutic approach...
PR Newswire
26/09/2023

Clario teams up with CellCarta to transform clinical trial sample management for…

This partnership aims to streamline the handling of tissue and samples and subsequent digitization in support of clinical trial endpoint generation across multiple therapeutic areas, including oncology, hepatology (e.g., NASH), and gastroenterology (e.g., UC and Crohn's). The collaboration also provides several options for sites to submit pathology data/samples, including fixed tissue, tissue blocks, glass slides or whole slide images. This flexibility increases the number of sites that could…
PR Newswire
26/09/2023

Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of delivery, today announced that it held an Investigator's Meeting with principal investigators at Brigham and Women's Hospital, a founding member of Mass General Brigham Healthcare System, to begin site initiation for its lead intranasal foralumab program entering Phase 2a clinical testing in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients...
Nasdaq GlobeNewswire
26/09/2023

COVID Taught the Public About RNAi Drug Delivery, now the Market is Booming

Clinical RNAi diagnostic tools and therapies are revolutionizing the pharmaceutical industry. With a projected Compound Annual Growth Rate (CAGR) of 20.5% between 2023 and 2028, the global nucleic acid treatment delivery market is set to experience an unprecedented surge in value. By 2028, the market, currently valued at $900 million, will reach a staggering $2.6 billion, analysts estimate. Clinical RNAi diagnostic tools and therapies are revolutionizing the pharmaceutical industry. With a...
PR Newswire
26/09/2023

Infectious Disease Research Through Unmet Needs Analysis, Pipeline Assessment…

To assist them in their endeavours, Disease Landscape Insights (DLI) has been offering its deep dive expertise to the firms or organizations dealing with infectious disease research and treatment. To assist them in their endeavours, Disease Landscape Insights (DLI) has been offering its deep dive expertise to the firms or organizations dealing with infectious disease research and treatment. DLI is leaving no stones unturned in revolution the field of infectious disease research and treatment...
PR Newswire
26/09/2023

AliveCor's KardiaMobile® 6L Becomes First Personal ECG Device Recommended for…

"Timely ECG monitoring of patients who are on antipsychotic medication can save lives. Having access to KardiaMobile 6L will mean potentially vulnerable patients can now be seen in the comfort of their homes, reducing their stress whilst ensuring that this essential monitoring is completed anywhere, at any time. It's encouraging that NICE has recognised the need for early access to this important technology," said Dr Mani Krishnan, Consultant Psychiatrist and Specialty Clinical…
PR Newswire
26/09/2023

WuXi Vaccines Launches Its First Vaccines CDMO Site in China

Mr. Jian Dong, CEO of WuXi Vaccines, commented, "We are very pleased with the opening at our first standalone vaccine CDMO site in China. This is a great achievement for our company as it allows us to significantly expand our services and capacities. We look forward to working with our global partners to advance their pipelines, with the ultimate goal of improving the well-being of people worldwide." Mr.Jian Dong, CEO of WuXi Vaccines, commented, "We are very pleased with the…
PR Newswire
26/09/2023
Altri  Comunicati